- Disease: Respiratory syncytial virus infection
- Study type: Observational Cohort Study, Prevention
- Study type descriptors: Retrospective, Single centre
- Objective: To investigate the efficacy and safety of nirsevimab in a cohort of term and preterm newborns during the 2024–2025 RSV season, and compare the results to the data obtained from the two preceding epidemic seasons
- Number of participants enrolled: 2035
- Study enrolling from to
- Study includes follow-up for 30 days
Study Data
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to